valsartan aurobindo 40 milligram film coated tablet
milpharm limited - valsartan - film coated tablet - 40 milligram - angiotensin ii antagonists, plain
valsartan aurobindo 80 milligram film coated tablet
milpharm limited - valsartan - film coated tablet - 80 milligram - angiotensin ii antagonists, plain
valsartan aurobindo 160 milligram film coated tablet
milpharm limited - valsartan - film coated tablet - 160 milligram - angiotensin ii antagonists, plain
valsartan aurobindo 320 milligram film coated tablet
milpharm limited - valsartan - film coated tablet - 320 milligram - angiotensin ii antagonists, plain
valsartan / hydrochlorothiazide teva 80 mg/12.5 mg film-coated tablets
teva pharma b.v. - valsartan; hydrochlorothiazide - film-coated tablet - 80 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics
amlodipine/valsartan teva 5/80 milligram film coated tablet
teva b.v. - valsartan, amlodipine besilate - film coated tablet - 5/80 milligram - angiotensin ii antagonists and calcium channel blockers
amlodipine/valsartan teva 5/160 milligram film coated tablet
teva b.v. - valsartan, amlodipine besilate - film coated tablet - 5/160 milligram - angiotensin ii antagonists and calcium channel blockers
amlodipine/valsartan teva 10/160 milligram film coated tablet
teva b.v. - valsartan, amlodipine besilate - film coated tablet - 10/160 milligram - angiotensin ii antagonists and calcium channel blockers
valsartan tablet, film coated
northwind pharmaceuticals, llc - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 80 mg - 1.1 hypertension valsartan tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee
valsartan and hydrochlorothiazide- valsartan and hydrochlorothiazide tablet, film coated
remedyrepack inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progra